Shares of Evolent Health, Inc. (NYSE:EVH - Get Free Report) fell 3.1% on Monday . The company traded as low as $8.06 and last traded at $8.01. 83,506 shares were traded during mid-day trading, a decline of 97% from the average session volume of 2,413,539 shares. The stock had previously closed at $8.27.
Analyst Ratings Changes
Several analysts have commented on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a research note on Monday, March 10th. UBS Group lifted their price target on shares of Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Needham & Company LLC reiterated a "buy" rating and set a $15.00 price target on shares of Evolent Health in a research report on Tuesday, May 13th. Truist Financial dropped their price objective on shares of Evolent Health from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, April 10th. Finally, Piper Sandler reiterated an "overweight" rating and set a $16.00 price target (down from $17.00) on shares of Evolent Health in a report on Friday, February 21st. One research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $17.79.
Get Our Latest Stock Analysis on EVH
Evolent Health Price Performance
The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The stock has a market capitalization of $961.98 million, a PE ratio of -10.02 and a beta of 0.87. The stock's 50-day moving average is $8.94 and its 200 day moving average is $9.92.
Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The technology company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.08 by ($0.02). Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The firm had revenue of $483.65 million for the quarter, compared to analysts' expectations of $460.15 million. During the same quarter in the prior year, the business earned $0.34 EPS. The company's quarterly revenue was down 24.4% compared to the same quarter last year. As a group, equities analysts expect that Evolent Health, Inc. will post 0.08 earnings per share for the current year.
Institutional Investors Weigh In On Evolent Health
Several large investors have recently modified their holdings of the stock. Brighton Jones LLC purchased a new position in Evolent Health during the 4th quarter worth $3,927,000. Congress Asset Management Co. raised its holdings in Evolent Health by 115.6% during the fourth quarter. Congress Asset Management Co. now owns 224,284 shares of the technology company's stock worth $2,523,000 after purchasing an additional 120,261 shares in the last quarter. Principal Financial Group Inc. lifted its position in Evolent Health by 8.8% in the fourth quarter. Principal Financial Group Inc. now owns 62,455 shares of the technology company's stock valued at $703,000 after purchasing an additional 5,073 shares during the period. AlphaCentric Advisors LLC purchased a new stake in Evolent Health in the 4th quarter valued at approximately $61,000. Finally, Peregrine Capital Management LLC boosted its holdings in Evolent Health by 65.0% in the 4th quarter. Peregrine Capital Management LLC now owns 503,601 shares of the technology company's stock valued at $5,666,000 after purchasing an additional 198,358 shares in the last quarter.
Evolent Health Company Profile
(
Get Free Report)
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evolent Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolent Health wasn't on the list.
While Evolent Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
